

LAW OFFICES

23591

**WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS**

A PARTNERSHIP INCLUDING PROFESSIONAL CORPORATIONS


ONE LIBERTY PLACE - 46TH FLOOR  
PHILADELPHIA, PA 19103-7301

(215) 568-3100

Facsimile: (215) 568-3439

Cable: WOODCOCK

DATE: August 8, 1997



Please deliver this and the following pages to:

Name: A. MARSCHEL - GROUP 1807

Company/Firm: U.S. Patent and Trademark Office

Telecopier No.: ~~703-305-3014~~ 703-305-3014 OR

703-308-4227

Client/Matter No.: ISIS-1158

SENDER'S NAME: Michael P. Straher

PAGES TO FOLLOW: 13

If transmission is not complete, please call (215) 568-3100.

COVER MESSAGE:

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERY OF THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

DOCKET NO.: ISIS-1158

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Buchardt et al.

Serial No.: 08/319,411

Group No.: 1807


Filed: October 6, 1994 Examiner: A. Marschel

For: PEPTIDE NUCLEIC ACID CONJUGATES

## Certificate of Facsimile Transmission

I hereby certify that this paper is being facsimile transmitted to the Assistant Commissioner for Patents on the date shown below.

On August 8, 1997

  
Michael P. Straher Reg. No. 38,325

Assistant Commissioner for Patents  
Washington DC 20231

Sir:

AMENDMENT TRANSMITTAL LETTER

Transmitted herewith is an amendment in the above-identified application responsive to the Office Action dated July 8, 1997.

- ( ) Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
  - ( ) A verified statement claiming small entity status under 37 CFR 1.9 and 1.27 is enclosed.
  - ( ) Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR §§ 1.821 through 1.825.
- (XX) No additional fee is required.
-

The fee for additional claims presented in this amendment has been calculated as follows:

SMALL ENTITY							OTHER THAN SMALL ENTITY	
	Claims Remaining After Amendment	Highest Number Previously Paid for	No. Extra	Rate	Fee	OR	Rate	Fee
Total Claims	36 - 30	36 = (at least 20)	0	x\$11=	\$	OR	x\$22=	\$0
Indep. Claims	4 - 3	4 = (at least 3)	0	x\$40=	\$	OR	x\$80=	\$0
First Presentation Multiple Dependent Claims				+	\$130=	\$	OR	\$260=
Total fee for added claims:					\$			\$0

( ) Please charge my Deposit Account No. 23-3050 in the amount of \$\_\_\_\_. This sheet is attached in triplicate.

( ) A check in the amount of \$\_\_\_\_ is attached. Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

(XX) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in triplicate.

(XX) Any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims.


(XX) Any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).

(XX) The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in triplicate.

(XX) Any patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).

- ( ) The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).
- (XX) Any filing fees under 37 CFR 1.16 including fees for presentation of extra claims.

Date: August 8, 1997

  
Michael P. Straher  
Registration No. 38,325

WOODCOCK WASHBURN KURTZ  
MACKIEWICZ & NORRIS LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
(215) 568-3100

#1316 8/20/97  
Bray  
PATENT

DOCKET NO.: ISIS-1158

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Nielsen, et al.

Serial No.: 08/319,411

Group Art Unit: 1807

Filed: October 6, 1994

Examiner: A. Marschel

For: PEPTIDE NUCLEIC ACID CONJUGATES

## Certificate of Facsimile Transmission

I hereby certify that this paper is being facsimile transmitted to the Assistant Commissioner for Patents on the date shown below.

On August 8, 1997

  
Michael P. Straher Reg. No. 38,325

Assistant Commissioner  
for Patents  
Washington, D.C. 20231

## RESPONSE TO COMMUNICATION

In response to the Communication mailed July 8, 1997, in connection with the above-captioned patent application, Applicants respectfully request that the following amendments be entered, without prejudice:

## In the Claims:

In the first line of each of claims 8, 9, 10, 11, 14, 16, 18, 19 and 20, delete "7" and substitute --37-- therefor.

In the first line of each of claims 22, 23, 24, 25, 26, 27, 28 and 29, delete "21" and substitute --38-- therefor.